カテゴリー： Market Monitor Global, 世界, 医療/バイオ

尿路感染症（UTI）治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Urinary Tract Infection (UTI) Medications Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2229）

◆商品コード：MMG23FB2229
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：62
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の尿路感染症（UTI）治療薬市場規模と予測を収録しています。・世界の尿路感染症（UTI）治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の尿路感染症（UTI）治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の尿路感染症（UTI）治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ジェネリック医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

尿路感染症（UTI）治療薬のグローバル主要企業は、Pfizer、AstraZeneca、Novartis International、Johnson & Johnson、Roche Holding AG、Teva Pharmaceutical lndustries、Boehringer Ingelheim、Cipla、AdvaCare Pharma、Baiyunshan Pharma、Harbin Pharmaceutical Group、Aurobindo Pharma、Alkem Laboratories、Ascend Laboratoriesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、尿路感染症（UTI）治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の尿路感染症（UTI）治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の尿路感染症（UTI）治療薬市場：タイプ別市場シェア、2022年
・ジェネリック医薬品、先発医薬品

世界の尿路感染症（UTI）治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の尿路感染症（UTI）治療薬市場：用途別市場シェア、2022年
・病院薬局、小売薬局、Eコマース

世界の尿路感染症（UTI）治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の尿路感染症（UTI）治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における尿路感染症（UTI）治療薬のグローバル売上、2018年-2023年
・主要企業における尿路感染症（UTI）治療薬のグローバル売上シェア、2022年
・主要企業における尿路感染症（UTI）治療薬のグローバル販売量、2018年-2023年
・主要企業における尿路感染症（UTI）治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、AstraZeneca、Novartis International、Johnson & Johnson、Roche Holding AG、Teva Pharmaceutical lndustries、Boehringer Ingelheim、Cipla、AdvaCare Pharma、Baiyunshan Pharma、Harbin Pharmaceutical Group、Aurobindo Pharma、Alkem Laboratories、Ascend Laboratories

*************************************************************

・調査・分析レポートの概要
尿路感染症（UTI）治療薬市場の定義
市場セグメント
世界の尿路感染症（UTI）治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の尿路感染症（UTI）治療薬市場規模
世界の尿路感染症（UTI）治療薬市場規模：2022年 VS 2029年
世界の尿路感染症（UTI）治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの尿路感染症（UTI）治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の尿路感染症（UTI）治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ジェネリック医薬品、先発医薬品
尿路感染症（UTI）治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院薬局、小売薬局、Eコマース
尿路感染症（UTI）治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別尿路感染症（UTI）治療薬市場規模 2022年と2029年
地域別尿路感染症（UTI）治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、AstraZeneca、Novartis International、Johnson & Johnson、Roche Holding AG、Teva Pharmaceutical lndustries、Boehringer Ingelheim、Cipla、AdvaCare Pharma、Baiyunshan Pharma、Harbin Pharmaceutical Group、Aurobindo Pharma、Alkem Laboratories、Ascend Laboratories
...

This report aims to provide a comprehensive presentation of the global market for Urinary Tract Infection (UTI) Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urinary Tract Infection (UTI) Medications. This report contains market size and forecasts of Urinary Tract Infection (UTI) Medications in global, including the following market information:
Global Urinary Tract Infection (UTI) Medications Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Urinary Tract Infection (UTI) Medications market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Generic Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Urinary Tract Infection (UTI) Medications include Pfizer, AstraZeneca, Novartis International, Johnson & Johnson, Roche Holding AG, Teva Pharmaceutical lndustries, Boehringer Ingelheim, Cipla and AdvaCare Pharma, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Urinary Tract Infection (UTI) Medications companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Urinary Tract Infection (UTI) Medications Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Urinary Tract Infection (UTI) Medications Market Segment Percentages, by Type, 2022 (%)
Generic Drugs
Original Drug
Global Urinary Tract Infection (UTI) Medications Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Urinary Tract Infection (UTI) Medications Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Global Urinary Tract Infection (UTI) Medications Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Urinary Tract Infection (UTI) Medications Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urinary Tract Infection (UTI) Medications revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Urinary Tract Infection (UTI) Medications revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
AstraZeneca
Novartis International
Johnson & Johnson
Roche Holding AG
Teva Pharmaceutical lndustries
Boehringer Ingelheim
Cipla
AdvaCare Pharma
Baiyunshan Pharma
Harbin Pharmaceutical Group
Aurobindo Pharma
Alkem Laboratories
Ascend Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Urinary Tract Infection (UTI) Medications, market overview.
Chapter 2: Global Urinary Tract Infection (UTI) Medications market size in revenue.
Chapter 3: Detailed analysis of Urinary Tract Infection (UTI) Medications company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Urinary Tract Infection (UTI) Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Urinary Tract Infection (UTI) Medications Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Urinary Tract Infection (UTI) Medications Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Urinary Tract Infection (UTI) Medications Overall Market Size
2.1 Global Urinary Tract Infection (UTI) Medications Market Size: 2022 VS 2029
2.2 Global Urinary Tract Infection (UTI) Medications Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Urinary Tract Infection (UTI) Medications Players in Global Market
3.2 Top Global Urinary Tract Infection (UTI) Medications Companies Ranked by Revenue
3.3 Global Urinary Tract Infection (UTI) Medications Revenue by Companies
3.4 Top 3 and Top 5 Urinary Tract Infection (UTI) Medications Companies in Global Market, by Revenue in 2022
3.5 Global Companies Urinary Tract Infection (UTI) Medications Product Type
3.6 Tier 1, Tier 2 and Tier 3 Urinary Tract Infection (UTI) Medications Players in Global Market
3.6.1 List of Global Tier 1 Urinary Tract Infection (UTI) Medications Companies
3.6.2 List of Global Tier 2 and Tier 3 Urinary Tract Infection (UTI) Medications Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Urinary Tract Infection (UTI) Medications Market Size Markets, 2022 & 2029
4.1.2 Generic Drugs
4.1.3 Original Drug
4.2 By Type – Global Urinary Tract Infection (UTI) Medications Revenue & Forecasts
4.2.1 By Type – Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2023
4.2.2 By Type – Global Urinary Tract Infection (UTI) Medications Revenue, 2024-2029
4.2.3 By Type – Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Urinary Tract Infection (UTI) Medications Market Size, 2022 & 2029
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 E-Commerce
5.2 By Application – Global Urinary Tract Infection (UTI) Medications Revenue & Forecasts
5.2.1 By Application – Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2023
5.2.2 By Application – Global Urinary Tract Infection (UTI) Medications Revenue, 2024-2029
5.2.3 By Application – Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Urinary Tract Infection (UTI) Medications Market Size, 2022 & 2029
6.2 By Region – Global Urinary Tract Infection (UTI) Medications Revenue & Forecasts
6.2.1 By Region – Global Urinary Tract Infection (UTI) Medications Revenue, 2018-2023
6.2.2 By Region – Global Urinary Tract Infection (UTI) Medications Revenue, 2024-2029
6.2.3 By Region – Global Urinary Tract Infection (UTI) Medications Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.3.2 US Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.3.3 Canada Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.3.4 Mexico Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.4.2 Germany Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.3 France Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.4 U.K. Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.5 Italy Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.6 Russia Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.7 Nordic Countries Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.4.8 Benelux Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.5.2 China Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.3 Japan Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.4 South Korea Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.5 Southeast Asia Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.5.6 India Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.6.2 Brazil Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.6.3 Argentina Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Urinary Tract Infection (UTI) Medications Revenue, 2018-2029
6.7.2 Turkey Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7.3 Israel Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7.4 Saudi Arabia Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
6.7.5 UAE Urinary Tract Infection (UTI) Medications Market Size, 2018-2029
7 Urinary Tract Infection (UTI) Medications Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Urinary Tract Infection (UTI) Medications Major Product Offerings
7.1.4 Pfizer Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Urinary Tract Infection (UTI) Medications Major Product Offerings
7.2.4 AstraZeneca Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Novartis International
7.3.1 Novartis International Company Summary
7.3.2 Novartis International Business Overview
7.3.3 Novartis International Urinary Tract Infection (UTI) Medications Major Product Offerings
7.3.4 Novartis International Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.3.5 Novartis International Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Urinary Tract Infection (UTI) Medications Major Product Offerings
7.4.4 Johnson & Johnson Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 Roche Holding AG
7.5.1 Roche Holding AG Company Summary
7.5.2 Roche Holding AG Business Overview
7.5.3 Roche Holding AG Urinary Tract Infection (UTI) Medications Major Product Offerings
7.5.4 Roche Holding AG Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.5.5 Roche Holding AG Key News & Latest Developments
7.6 Teva Pharmaceutical lndustries
7.6.1 Teva Pharmaceutical lndustries Company Summary
7.6.2 Teva Pharmaceutical lndustries Business Overview
7.6.3 Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Major Product Offerings
7.6.4 Teva Pharmaceutical lndustries Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.6.5 Teva Pharmaceutical lndustries Key News & Latest Developments
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Company Summary
7.7.2 Boehringer Ingelheim Business Overview
7.7.3 Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Major Product Offerings
7.7.4 Boehringer Ingelheim Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.7.5 Boehringer Ingelheim Key News & Latest Developments
7.8 Cipla
7.8.1 Cipla Company Summary
7.8.2 Cipla Business Overview
7.8.3 Cipla Urinary Tract Infection (UTI) Medications Major Product Offerings
7.8.4 Cipla Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.8.5 Cipla Key News & Latest Developments
7.9 AdvaCare Pharma
7.9.1 AdvaCare Pharma Company Summary
7.9.2 AdvaCare Pharma Business Overview
7.9.3 AdvaCare Pharma Urinary Tract Infection (UTI) Medications Major Product Offerings
7.9.4 AdvaCare Pharma Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.9.5 AdvaCare Pharma Key News & Latest Developments
7.10 Baiyunshan Pharma
7.10.1 Baiyunshan Pharma Company Summary
7.10.2 Baiyunshan Pharma Business Overview
7.10.3 Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Major Product Offerings
7.10.4 Baiyunshan Pharma Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.10.5 Baiyunshan Pharma Key News & Latest Developments
7.11 Harbin Pharmaceutical Group
7.11.1 Harbin Pharmaceutical Group Company Summary
7.11.2 Harbin Pharmaceutical Group Business Overview
7.11.3 Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Major Product Offerings
7.11.4 Harbin Pharmaceutical Group Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.11.5 Harbin Pharmaceutical Group Key News & Latest Developments
7.12 Aurobindo Pharma
7.12.1 Aurobindo Pharma Company Summary
7.12.2 Aurobindo Pharma Business Overview
7.12.3 Aurobindo Pharma Urinary Tract Infection (UTI) Medications Major Product Offerings
7.12.4 Aurobindo Pharma Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.12.5 Aurobindo Pharma Key News & Latest Developments
7.13 Alkem Laboratories
7.13.1 Alkem Laboratories Company Summary
7.13.2 Alkem Laboratories Business Overview
7.13.3 Alkem Laboratories Urinary Tract Infection (UTI) Medications Major Product Offerings
7.13.4 Alkem Laboratories Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.13.5 Alkem Laboratories Key News & Latest Developments
7.14 Ascend Laboratories
7.14.1 Ascend Laboratories Company Summary
7.14.2 Ascend Laboratories Business Overview
7.14.3 Ascend Laboratories Urinary Tract Infection (UTI) Medications Major Product Offerings
7.14.4 Ascend Laboratories Urinary Tract Infection (UTI) Medications Revenue in Global Market (2018-2023)
7.14.5 Ascend Laboratories Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 尿路感染症（UTI）治療薬の世界市場見通し2023年-2029年(Urinary Tract Infection (UTI) Medications Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

尿路感染症（UTI）治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp